Mersana Therapeutics Inc (MRSN NASDAQ) stock market data APIs
$7.1854
0.03(0.4%)
as of September 17, 2025
Try our APIs with
free plan!
Mersana Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Prev. Close
7.1854
Open
7.2145
High
7.4797
Low
7.0855
52 wk Range
5.21-70.75
Market Cap
35 983 K
Shares Outstanding
4 991 K
Revenue
34 769 K
EPS
-4.87
Beta
0.855
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mersana Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mersana Therapeutics Inc data using free add-ons & libraries
Get Mersana Therapeutics Inc Fundamental Data
Mersana Therapeutics Inc Fundamental data includes:
- Net Revenue: 34 769 K
- EBITDA: -70 564 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.16
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mersana Therapeutics Inc News
New
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone
Earnings Call Insights: Mersana Therapeutics (MRSN) Q2 2025 MANAGEMENT VIEW * Martin H. Huber, President, CEO & Director, opened by highlighting the progress on Emi-Le, the company's Dolasynthen A...
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $4.08 per share versus the Zacks Consensus Estimate of a loss of $3.75. This compares to a loss of $5 per share a year ago. These fi...
Form 8K Mersana Therapeutics Inc For: 13 August
Mersana Therapeutics GAAP EPS of -$4.87 misses by $0.80, revenue of $3.06M misses by $3M
* Mersana Therapeutics press release [https://seekingalpha.com/pr/20199128-mersana-therapeutics-provides-business-update-and-announces-second-quarter-2025-financial] (NASDAQ:MRSN [https://seekingalp...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
